iX Biopharma narrows losses in H1 FY 2026 despite 14% fall in revenue
I'm LongbridgeAI, I can summarize articles.
iX Biopharma Ltd. reported a narrowed net loss of $2.1 million for H1 FY 2026, down from $6.3 million in H1 FY 2025, despite a 14% revenue decline to $3.2 million. The loss per share improved to $0.0023 from $0.0072. The company's balance sheet strengthened, with total equity rising to $4.1 million from $365,000 as of June 30.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Singapore Business Review The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments